Zacks Investment Research on MSN

BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises

Shares of Beam Therapeutics BEAM were up 22.3% on Monday after the company outlined strategic priorities and some expected ...

Beam Therapeutics (BEAM) Valuation After FDA Alignment And Extended Cash Runway To 2029

Why Beam Therapeutics Is Back On Investors’ Radar Beam Therapeutics (BEAM) is in focus after securing U.S. FDA alignment on a ...

Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating ...

Beam is building a platform approach for single-course, precision gene editing therapies for liver-targeted genetic diseases by delivering base editors through intravenous infusion of ...